Latest & greatest articles for phentermine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on phentermine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on phentermine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for phentermine

1. Randomised controlled trial: The combination of phentermine and topiramate is an effective adjunct to diet and lifestyle modification for weight loss and measures of comorbidity in overweight or obese adults with additional metabolic risk factors

Randomised controlled trial: The combination of phentermine and topiramate is an effective adjunct to diet and lifestyle modification for weight loss and measures of comorbidity in overweight or obese adults with additional metabolic risk factors The combination of phentermine and topiramate is an effective adjunct to diet and lifestyle modification for weight loss and measures of comorbidity in overweight or obese adults with additional metabolic risk factors | BMJ Evidence-Based Medicine We (...) of institutional accounts Username * Password * your user name or password? You are here The combination of phentermine and topiramate is an effective adjunct to diet and lifestyle modification for weight loss and measures of comorbidity in overweight or obese adults with additional metabolic risk factors Article Text Therapeutics Randomised controlled trial The combination of phentermine and topiramate is an effective adjunct to diet and lifestyle modification for weight loss and measures of comorbidity

2012 Evidence-Based Medicine (Requires free registration)

2. Cardiometabolic Disease Staging Predicts Effectiveness of Weight Loss Therapy to Prevent Type 2 Diabetes: Pooled Results From Phase III Clinical Trials Assessing Phentermine/Topiramate Extended Release

Cardiometabolic Disease Staging Predicts Effectiveness of Weight Loss Therapy to Prevent Type 2 Diabetes: Pooled Results From Phase III Clinical Trials Assessing Phentermine/Topiramate Extended Release To assess the ability of medication-assisted weight loss to prevent diabetes as a function of the baseline weighted Cardiometabolic Disease Staging (CMDS) score.We pooled data from 3,040 overweight and obese participants in three randomized controlled trials-CONQUER, EQUIP, and SEQUEL-assessing (...) efficacy and safety of phentermine/topiramate extended release (ER) for weight loss. In these double-blind phase III trials, overweight/obese adult patients were treated with a lifestyle intervention and randomly assigned to placebo versus once-daily oral phentermine/topiramate ER. The weighted CMDS score was calculated using baseline quantitative clinical data including waist circumference, blood glucose, blood pressure, and blood lipids. Incident diabetes was defined based on serial measures

2017 EvidenceUpdates

3. Topiramate + phentermine (Qsiva and other brands): an excessively dangerous appetite-suppressant combination

Topiramate + phentermine (Qsiva and other brands): an excessively dangerous appetite-suppressant combination Prescrire IN ENGLISH - Spotlight: Archive ''Topiramate + phentermine (Qsiva° and other brands): an excessively dangerous appetite-suppressant combination'', 1 March 2013 {1} {1} {1} | | > > > Topiramate + phentermine (Qsiva° and other brands): an excessively dangerous appetite-suppressant combination Spotlight: Archives Every month, the subjects in Prescrire’s Spotlight. 2013 :   (...) |   |  Spotlight Archives Topiramate + phentermine (Qsiva° and other brands): an excessively dangerous appetite-suppressant combination FEATURED REVIEW Overweight and obese patients must not be exposed to the topiramate + phentermine combination. No beneficial impact on clinical complications of obesity has been demonstrated. A portion of the weight lost is regained after treatment withdrawal. And numerous serious adverse effects have already been observed. Full review (4 pages) available

2014 Prescrire

4. Comparison of the Effect of Intense-Exercise/Moderate-Calorie, Topiramate-Phentermine and Cognitive Behavioral Therapy on Obesity

Comparison of the Effect of Intense-Exercise/Moderate-Calorie, Topiramate-Phentermine and Cognitive Behavioral Therapy on Obesity Comparison of the Effect of Intense-Exercise/Moderate-Calorie, Topiramate-Phentermine and Cognitive Behavioral Therapy on Obesity - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have (...) reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Comparison of the Effect of Intense-Exercise/Moderate-Calorie, Topiramate-Phentermine and Cognitive Behavioral Therapy on Obesity The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01970566 Recruitment

2013 Clinical Trials

5. Suprenza (phentermine hydrochloride) orally dissolving tablets

Suprenza (phentermine hydrochloride) orally dissolving tablets Drug Approval Package: Suprenza (phentermine hydrochloride) NDA #202088 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Suprenza (phentermine hydrochloride) orally dissolving tablets, 15 mg and 30 mg Company: Citius Pharmaceuticals, LLC Application No.: 202088 Approval Date: 06/13/2011 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634

2011 FDA - Drug Approval Package

6. Coadministration of lorcaserin and phentermine for weight management: A 12-week, randomized, pilot safety study. (PubMed)

Coadministration of lorcaserin and phentermine for weight management: A 12-week, randomized, pilot safety study. To assess the short-term tolerability of lorcaserin alone or with two dose regimens of phentermine.This was a 12-week, randomized, double-blind, pilot safety study of N = 238 nondiabetic patients with obesity or overweight with ≥1 comorbidity randomized to lorcaserin 10 mg twice daily (BID; LOR BID) alone or with phentermine 15 mg once daily (QD; LOR BID+PHEN QD) or 15 mg twice daily (...) , LOR BID+PHEN QD, and LOR BID+PHEN BID, respectively. At least 5% WL was achieved by 28.2% LOR BID, 59.0% LOR BID+PHEN QD (P = 0.0002 vs. LOR BID), and 70.9% LOR BID+PHEN BID (P < 0.0001 vs. LOR BID) patients.Phentermine added to lorcaserin enhanced short-term weight loss but did not increase incidence of potentially serotonergic AEs; however, phentermine twice daily increased discontinuation compared to both lorcaserin alone and lorcaserin plus phentermine once daily.© 2017 The Authors. Obesity

Full Text available with Trip Pro

2017 Obesity

7. Coadministration of Canagliflozin and Phentermine for Weight Management in Overweight and Obese Individuals Without Diabetes: A Randomized Clinical Trial. (PubMed)

Coadministration of Canagliflozin and Phentermine for Weight Management in Overweight and Obese Individuals Without Diabetes: A Randomized Clinical Trial. To assess the efficacy and safety of coadministration of canagliflozin (CANA) and phentermine (PHEN) compared with placebo (PBO) and CANA or PHEN monotherapies in individuals who were overweight and obese without type 2 diabetes.This 26-week, phase 2a, randomized, double-blind, PBO-controlled, multicenter, parallel-group study enrolled

Full Text available with Trip Pro

2017 Diabetes Care

8. Effects of a meal replacement system alone or in combination with phentermine on weight loss and food cravings. (PubMed)

Effects of a meal replacement system alone or in combination with phentermine on weight loss and food cravings. To examine the effects of phentermine combined with a meal replacement program on weight loss and food cravings and to investigate the relationship between food cravings and weight loss.In a 12-week randomized, double-blind, placebo-controlled clinical trial, 77 adults with obesity received either phentermine or placebo. All participants were provided Medifast® meal replacements, were (...) instructed to follow the Take Shape for Life® Optimal Weight 5&1 Plan for weight loss, and received lifestyle coaching in the Habits of Health program. The Food Craving Inventory and the General Food Cravings State and Trait Questionnaires were used to measure food cravings.The phentermine group lost 12.1% of baseline body weight compared with 8.8% in the placebo group. Cravings for all food groups decreased in both groups; however, there was a greater reduction in cravings for fats and sweets

2016 Obesity

9. The New Weight-Loss Drugs, Lorcaserin and Phentermine-Topiramate: Slim Pickings? (PubMed)

The New Weight-Loss Drugs, Lorcaserin and Phentermine-Topiramate: Slim Pickings? In 2012, the US Food and Drug Administration approved 2 drugs for long-term weight loss: lorcaserin hydrochloride (Belviq; Eisai Inc) and phentermine-topiramate (Qysmia; Vivus Inc). The approvals were based on 1-year trials showing that on top of recommendations to follow a calorie-restricted diet and to increase exercise, patients randomized to either drug lost more weight than patients randomized to placebo (3 (...) % [95% CI, 3%-4%] more weight lost with lorcaserin; 7% [95% CI, 3%-4%] more with phentermine /topiramate). The drugs have been associated with serious harms: Both drugs' labels include warnings about memory, attention, or language problems and depression; for lorcaserin, the label also warns of valvular heart disease and euphoria; and for phentermine-topiramate, the label warns of metabolic acidosis, increased heart rate, anxiety, insomnia, and elevated creatinine levels. Neither medication

2014 JAMA Internal Medicine

10. Steady-state pharmacokinetics of phentermine extended-release capsules. (PubMed)

Steady-state pharmacokinetics of phentermine extended-release capsules. Twenty-one healthy, caucasian, male volunteers completed this randomized single blind, multiple-dose, crossover bioavailability study during which either phentermine HCl capsules (Minobese Forte, reference product) or phentermine base capsules (Duromine, test product) were ingested once daily for 14 days. A washout period of 14 days was allowed between the two treatment phases. On profile days (day 14 of each treatment (...) phase) subjects remained recumbent for 24 hours after drug administration. Serial venous blood samples were drawn over the 24 hour dosing interval for plasma phentermine assay by gas chromatography. The 90% confidence intervals for the "test/reference" mean ratios of the pharmacokinetic variables Cmax,norm, Cmin,norm, AUCnorm (normalized for difference in the dose of phentermine base), %PTF and T75% Cmax, all fell within the bioequivalence range of 80% to 125%. With the aid of trough plasma

1993 International journal of clinical pharmacology, therapy, and toxicology

11. Effects of Co-administration of Canagliflozin 300 mg and Phentermine 15 mg With Placebo in the Treatment of Non-Diabetic Overweight and Obese Participants

Effects of Co-administration of Canagliflozin 300 mg and Phentermine 15 mg With Placebo in the Treatment of Non-Diabetic Overweight and Obese Participants Effects of Co-administration of Canagliflozin 300 mg and Phentermine 15 mg With Placebo in the Treatment of Non-Diabetic Overweight and Obese Participants - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail (...) Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Effects of Co-administration of Canagliflozin 300 mg and Phentermine 15 mg With Placebo in the Treatment of Non-Diabetic Overweight and Obese Participants The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government

2014 Clinical Trials

12. The Effect of Phentermine and B12 on Weight Loss Among Obese Patients

The Effect of Phentermine and B12 on Weight Loss Among Obese Patients The Effect of Phentermine and B12 on Weight Loss Among Obese Patients - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. The Effect (...) of Phentermine and B12 on Weight Loss Among Obese Patients The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01719185 Recruitment Status : Completed First Posted : November 1, 2012 Last Update Posted : August 13, 2015 Sponsor: Dr. Michael Lang Information provided by (Responsible Party): Dr. Michael Lang, East

2012 Clinical Trials

13. Studying the Effects of Phentermine on Eating Behavior

Studying the Effects of Phentermine on Eating Behavior Studying the Effects of Phentermine on Eating Behavior - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Studying the Effects of Phentermine on Eating (...) by (Responsible Party): New York State Psychiatric Institute Study Details Study Description Go to Brief Summary: The goal of this study is to determine whether one week of phentermine compared to placebo administration results in changes in food intake during a laboratory meal. Condition or disease Intervention/treatment Phase Obesity Drug: Phentermine Drug: placebo Phase 4 Detailed Description: This study aims to explore whether short-term measures of eating behavior can be related to later, longer-term

2013 Clinical Trials

14. Phentermine

Phentermine Phentermine Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Phentermine Phentermine Aka: Phentermine , Lonamin , Fastin (...) , Lomaira From Related Chapters II. Mechanism Stimulates CNS adrenergic system Reduces food seeking behavior III. Indication Short term (12 weeks per year) Physician discretion for indication to continue IV. Classifications Class IV (Limited dependence liability) V. Dosing Start: 8 mg orally three times daily Alternative: 15 to 37.5 mg orally daily 10 hours before sleep Images: Related links to external sites (from Bing) These images are a random sampling from a Bing search on the term "Phentermine

2015 FP Notebook

15. Qsiva - phentermine / topiramate

Qsiva - phentermine / topiramate 7 Westferry Circus ? Canary Wharf ? London E14 4HB ? United Kingdom An agency of the European Union Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7523 7455 E-mail info@ema.europa.eu Website www.ema.europa.eu © European Medicines Agency, 2013. Reproduction is authorised provided the source is acknowledged. 21 February 2013 EMA/CHMP/108692/2013 Committee for Medicinal Products for Human Use (CHMP) Assessment report Qsiva International non-proprietary name (...) : PHENTERMINE / TOPIRAMATE Procedure No. EMEA/H/C/002350/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. Qsiva CHMP assessment report EMA/CHMP/108692/2013 Page 2/91 Table of contents 1. Background information on the procedure 5 1.1. Submission of the dossier 5 1.2. Manufacturers 6 1.3. Steps taken for the assessment of the product 6 2. Scientific discussion 7 2.1. Introduction 7 2.2. Quality aspects 9 2.2.1. Introduction 9 2.2.2. Active

2013 European Medicines Agency - EPARs

16. Effect of Lorcaserin Alone and in Combination with Phentermine on Food Cravings After 12-Week Treatment: A Randomized Substudy. (PubMed)

Effect of Lorcaserin Alone and in Combination with Phentermine on Food Cravings After 12-Week Treatment: A Randomized Substudy. This study evaluated the effect of lorcaserin 10 mg twice daily (LOR BID), or with phentermine 15 mg once daily (LOR BID + PHEN QD) and 15 mg twice daily (LOR BID + PHEN BID), in conjunction with energy restriction on food cravings.Two hundred and thirty-five patients without diabetes but with obesity or overweight and ≥ 1 comorbidity received LOR BID, LOR BID + PHEN (...) . Cravings assessed by COEQ reduced from baseline in all groups. In general, the combination treatments were more effective than lorcaserin alone. At week 12, except for fruit juice and dairy products, general and specific cravings reduced in LOR BID + PHEN BID compared with LOR BID (P < 0.05).Lorcaserin in combination with phentermine improves control of food cravings during short-term energy restriction.© 2018 The Obesity Society.

2018 Obesity

17. The new weight-loss drugs, lorcaserin and phentermine-topiramate: slim pickings? (PubMed)

The new weight-loss drugs, lorcaserin and phentermine-topiramate: slim pickings? In 2012, the US Food and Drug Administration approved 2 drugs for long-term weight loss: lorcaserin hydrochloride (Belviq; Eisai Inc) and phentermine-topiramate (Qysmia; Vivus Inc). The approvals were based on 1-year trials showing that on top of recommendations to follow a calorie-restricted diet and to increase exercise, patients randomized to either drug lost more weight than patients randomized to placebo (3 (...) % [95% CI, 3%-4%] more weight lost with lorcaserin; 7% [95% CI, 3%-4%] more with phentermine /topiramate). The drugs have been associated with serious harms: Both drugs' labels include warnings about memory, attention, or language problems and depression; for lorcaserin, the label also warns of valvular heart disease and euphoria; and for phentermine-topiramate, the label warns of metabolic acidosis, increased heart rate, anxiety, insomnia, and elevated creatinine levels. Neither medication

2014 JAMA Internal Medicine

18. Orlistat/Phentermine Versus Placebo/Phentermine

Orlistat/Phentermine Versus Placebo/Phentermine Orlistat/Phentermine Versus Placebo/Phentermine - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Orlistat/Phentermine Versus Placebo/Phentermine The safety (...) , which in turn leads to an weight gain and a deterioration in physical performance. Among the drugs used for obesity, orlistat has been approved for long-term use, and phentermine, the most commonly used drug, has been approved for short-term use. However, phentermine can increase blood pressure and pulse rate. Meanwhile, several studies have shown that orlistat, a pancreatic lipase inhibitor, lowers blood pressure and pulse rate and diminish LDL-cholesterol. Lowering LDL-C could lead to improved

2018 Clinical Trials

19. Qsymia (phentermine and topiramate extended-release)

Qsymia (phentermine and topiramate extended-release) Drug Approval Package: Qsymia (phentermine and topiramate extended-release) NDA #22580Orig1s000 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Qsymia (phentermine and topiramate extended-release) Capsules CIV Company: Vivus, Inc. Application No.: 22580Orig1s000 Approval Date: 07/17/2012 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF

2012 FDA - Drug Approval Package

20. Suprenza (phentermine hydrochloride) orally dissolving tablets

Suprenza (phentermine hydrochloride) orally dissolving tablets Drug Approval Package: Suprenza (phentermine hydrochloride) NDA #202088 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Suprenza (phentermine hydrochloride) orally dissolving tablets (ODT), 15 mg, 30 mg, and 37.5 mg Company: Citius Pharmaceuticals, LLC Application No.: 202088 Approval Date: 03/27/2012 Persons with disabilities having problems accessing the PDF files below may call (301) 796

2012 FDA - Drug Approval Package